Steven Isakoff, MD
Hematology & Oncology · Boston, MANPI 1447205042
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,625 of the $20,160 with a category attached, or 82.5%. 10 manufacturers reported payments, led by AbbVie at 28.3% of the total. Reporting peaked in 2019 at $11,461 and has fallen 83.8% since, to $1,852 in 2025.
Across 31 payments — averaging $650.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Novartis$5K
- Puma Biotechnology, Inc.$4K
- F. Hoffmann-la Roche AG$2K
- AstraZeneca$2K
- Seagen Inc.$1K
- plus $657 from 4 others
Across 177 payments — averaging $44,497 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$6.1M
- Merck$811K
- AstraZeneca$332K
- Tesaro, Inc.$303K
- Genentech, Inc.$226K
- AbbVie$135K
- plus $6K from 1 others
What the payments were for
- Consulting fees$16,62582%
- Speaking & faculty fees$1,8969%
- Travel & lodging$7354%
- Food & beverage$8504%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $5,706 |
| Novartis | 2 | $5,000 |
| Puma Biotechnology, Inc. | 5 | $3,900 |
| F. Hoffmann-la Roche AG | 5 | $1,896 |
| AstraZeneca | 3 | $1,852 |
| Seagen Inc. | 1 | $1,150 |
| Hoffmann-la Roche Limited | 2 | $475 |
| Astrazeneca UK Limited | 1 | $135 |
| Roche Products Limited | 1 | $35 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,160 in reported general payments places this provider in the 75th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrserduElacestrant Hcl | 16 | $370,106 |
| Letrozole | 82 | $2,474 |
| Tamoxifen Citrate | 28 | $1,163 |
| Anastrozole | 21 | $447 |
| Prochlorperazine Maleate | 12 | $177 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.